Clinical Trial

Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2024 (before its estimated February 25, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective, single center, open label, single arm clinical study. Select resectable locally advanced (cT3-4aN0M0, cT1-3N1-2M0, cII/III stage) esophageal cancer with pathological diagnosis of squamous cell carcinoma for inclusion, receive pembrolizumab combined with platinum containing dual drug (albumin paclitaxel+carboplatin) treatment for 2 courses, and undergo surgery. After surgery, continue pembrolizumab immunotherapy. Using pCR as the main endpoint of the study
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-04.
Trial Details
NCT Number NCT06304350
Lead Sponsor Tongji University
Conditions Esophageal Cancer
Enrollment 25 participants
Start Date 2024-02-17
Primary Completion 2026-02-25 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-03-13